As CCR5 is expressed on the surface of breast cancer cells and leronlimab reduced CCR5-dependent cell-autonomous functions, including calcium signaling and cellular invasion, the impact of leronlimab in this case is likely mediated via a direct effect on the breast cancer cells. This evidence concerns the gene CCR5 and breast carcinoma.